



Update Summary

Entity name

RADIOPHARM THERANOSTICS LIMITED

Announcement Type

Update to previous announcement

Date of this announcement

9/8/2024

Reason for update to a previous announcement

- + Date of Extraordinary General Meeting amended from 5 to 14 August 2024 and consequential changes
- + Proposed issue date amended from 8 to 21 August 24
- + Option expiry date amended from 7 to 24 August 2026 per Notice of EGM
- + New description OPTION EXPIRING 24 AUG 2026 EX 0.06

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

RADIOPHARM THERANOSTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ACN

Registration Number

647877889

1.3 ASX issuer code

RAD

1.4 The announcement is

Update/amendment to previous announcement

1.4a Reason for update to a previous announcement

- + Date of Extraordinary General Meeting amended from 5 to 14 August 2024 and consequential changes
 - + Proposed issue date amended from 8 to 21 August 24
 - + Option expiry date amended from 7 to 24 August 2026 per Notice of EGM
 - + New description OPTION EXPIRING 24 AUG 2026 EX 0.06

1.4b Date of previous announcement to this update

25/6/2024

1.5 Date of this announcement

9/8/2024

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	14/8/2024	Actual	

Comments

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ASX +security code and description

RAD : ORDINARY FULLY PAID

Number of +securities proposed to be issued

965,837,798

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.04000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes



Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

New class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?

No

Will the entity be seeking quotation of the 'new' class of +securities on ASX?

Yes

ASX +security code

New class-code to be confirmed

+Security description

OPTION EXPIRING 7-AUG-2026 EX \$0.06

+Security type

Options

Number of +securities proposed to be issued

781,484,263

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Attaching options per Placement announced 25 June 2024

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Options details

+Security currency

AUD - Australian Dollar

Exercise price

AUD 0.0600

Expiry date

7/8/2026

**Details of the type of +security that will be issued if the option is exercised**

RAD : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One RAD ordinary fully paid share for each option exercised

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

New class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?

No

Will the entity be seeking quotation of the 'new' class of +securities on ASX?

Yes

ASX +security code

New class-code to be confirmed

+Security description

OPTION EXPIRING 7-AUG-2026 EX \$0.06

+Security type

Options

Number of +securities proposed to be issued

390,742,132

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Contingent options per Placement announced 25 June 2024

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes



Options details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.0600	7/8/2026

Details of the type of +security that will be issued if the option is exercised

RAD : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One RAD ordinary fully paid share for each option exercised

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Part 7C - Timetable

7C.1 Proposed +issue date

21/8/2024

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1
14/8/2024

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?
Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?
No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?
No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?
Yes

7E.1a Who is the lead manager/broker?

Bell Potter Securities Limited acted as lead manager to the capital raising and B. Riley Securities Inc acted as US placement agent.



7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Bell Potter Securities Limited:

1% (exclusive of GST) management fee on proceeds from Placement and SPP.

5% (exclusive of GST) selling fee on proceeds from Placement and SPP, excluding subscriptions by Lantheus, Paul Hopper and introduced by B Riley Inc.

1% option exercise fee on option exercise proceeds.

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

B. Riley Securities Inc:

6.5% on gross proceeds from Placement

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Proceeds from the capital raising will be used primarily for:

- drug manufacturing;
- clinical trials;
- general working capital; and
- funding the costs of the capital raising.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

Refer announcement released 25 June 2024 "Radiopharm Theranostics completes A\$70 million placement"

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a +disclosure document or +PDS for the +securities proposed to be issued